[New investment & listing/claim trend]

[New investment & listing/claim trend]
*Lunar New Year is just around the corner. The weather is getting warmer. I won’t eat rice cake soup this Lunar New Year as I’m a year older

*I’d like to talk about the new listing in the U.S. There were about 6 cases excluding SPAC. Half of them were new drug bio (3 cases) and local healthcare companies 1 case. As the nuances of changing the direction of liquidity are eased, people are flocking to growth stocks? I’m conservative, but..

• Shares of U.S.-listed bio stocks are also daunting. Fibrobiologics FBLG has an offering price of $30; today it is $15; Arrivent AVBP has an offering price of $18; now it is $21.85, now it is $11.1; and CG Oncology CGOG has an offering price of $19. Dynamic USA

*Should I say that the most interesting company is Kakao in Kazakhstan? Kaspi.kz , which provides fintech, payment, shopping, and B2B superapps. The name of the listed company is Joint Stock Co.Kaspi.kz (KSPI). The population of Kazakhstan is 19 million, and the MAU is 13 million. It looks like we are seeing Kakao in the old days. What’s scary is that the company has 2.8 billion dollars in sales and 1.3 billion dollars in net profit based on dollar conversion. Considering that Kazakhstan’s GDP is 1971 billion dollars as of 21 and the population is 19 million, is it Kakao?

• There is only one new claim company, K3I. There are three new approvals: Cochop, InnoGrid, and K&R System. There is no company that I’m craving..

*Angelobotics and Samhyun were among the companies that submitted the invoice. In the case of Samhyun, it had a net profit of 7.2 billion won and sales of 72.7 billion won, but it went up as a technical exception. Perhaps it is because of the integrated system of BM listing, but it is a case that went up as a special case of growth even though it is in the black. I’ll check this later… If I ask the manager on Sunday, I’ll also be criticized..

• There were 44 new investments. A large number of them were early-stage companies. Jinus, a hospital brand company, recorded the highest investment as it received 30 billion won in PEF. The company’s sales are 37.8 billion won and profits are based on 7.4 billion ’22 years. In addition, Daan Bio attracted 23 billion won, and hamburger manufacturing robot ANI recorded 15.7 billion won.